142 related articles for article (PubMed ID: 35000134)
1. Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan.
Terakawa K; Katagiri D; Shimada K; Sato L; Takano H
CEN Case Rep; 2022 Aug; 11(3):328-332. PubMed ID: 35000134
[TBL] [Abstract][Full Text] [Related]
2. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
[TBL] [Abstract][Full Text] [Related]
3. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
4. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV.
Sasaki H; Miyata N; Yoshimura Y; Tachikawa N
Infection; 2022 Jun; 50(3):771-774. PubMed ID: 35181864
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic.
Levey NH; Forrest AD; Spielman DW; Easley KA; Dude CM; Badell ML
Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100673. PubMed ID: 35671984
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.
Arikawa S; Fukuoka K; Nakamoto K; Kunitomo R; Matsuno Y; Shimazaki T; Saraya T; Kawakami T; Kishimoto M; Komagata Y; Kurai D; Ishi H; Kaname S
Clin Exp Nephrol; 2022 May; 26(5):476-485. PubMed ID: 35182277
[TBL] [Abstract][Full Text] [Related]
8. Casirivimab/Imdevimab: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
[TBL] [Abstract][Full Text] [Related]
9. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
Tuccori M; Convertino I; Ferraro S; Cappello E; Valdiserra G; de Luca G; Franchini M; Focosi D
Expert Opin Drug Discov; 2022 Jun; 17(6):531-546. PubMed ID: 35361043
[TBL] [Abstract][Full Text] [Related]
10. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
[TBL] [Abstract][Full Text] [Related]
11. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.
Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM
J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes.
Hayek S; Ben-Shlomo Y; Dagan N; Reis BY; Barda N; Kepten E; Roitman A; Shapira S; Yaron S; Balicer RD; Netzer D; Peretz A
Nat Commun; 2022 Aug; 13(1):4480. PubMed ID: 35918340
[TBL] [Abstract][Full Text] [Related]
13. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
[No Abstract] [Full Text] [Related]
14. Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.
Haskologlu IC; Erdag E; Sayiner S; Abacioglu N; Sehirli AO
Mol Biol Rep; 2022 May; 49(5):4061-4068. PubMed ID: 35389130
[TBL] [Abstract][Full Text] [Related]
15. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
[TBL] [Abstract][Full Text] [Related]
16. Real world utilization of REGEN-COV2 at a community hospital.
Ash J; Leavitt R; Dietrich T; Schritter S; Wells J; Santarelli A; Ashurst J
Am J Emerg Med; 2021 Dec; 50():129-131. PubMed ID: 34364110
[TBL] [Abstract][Full Text] [Related]
17. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
[TBL] [Abstract][Full Text] [Related]
19. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
20. Case Report of COVID-19 Infection After Kidney Transplant Treated With Casirivimab-Imdevimab and Mycophenolate Mofetil Changed to Everolimus.
Kijima Y; Shimizu T; Kato S; Kano K; Horiuchi T; Nozaki T; Omoto K; Inui M; Toma H; Iida S; Takagi T
Transplant Proc; 2022; 54(6):1561-1563. PubMed ID: 35065832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
